Wall Street bank: Fears on cannabis commoditization overdone

A New York-based investment bank initiated coverage of the cannabis industry Monday, another sign that Wall Street prudence is catching up to main street excitement over the burgeoning sector.

The global marijuana industry has a “base-case conservative” forecast worth roughly $50 billion in the next decade, Jefferies Group said in its initiating report, and a “realistic upside” size of $130 billion based on wider industry disruption.

Putting that into context, Jefferies estimates the industry is worth $17 billion today.

Key takeaways from the Jefferies report:

  • Global winners will be those who lead in both medical and recreational and have a strong U.S. position.
  • Fears on commoditization are overdone.
  • Expect to see further consolidation.
  • Near-term focus will shift to performance versus headlines and capacity expectations.

“If any cannabis (company) wants to claim large cap or even mega-cap future status, they need to have a strong position in the U.S.,” Jefferies analyst Owen Bennett wrote in the report.

“Although all coverage names are not currently allowed (to have) U.S. operations while it is federally illegal, they should still be establishing optionality for when/if U.S. regulations change.”

Bennett also said fears over price commoditization are overblown.

“The often-used bear argument on the cannabis space is that weed is just another agri commodity, and therefore all flower will become commoditized,” the report noted. “They also argue price compression will happen within the next 12 months due to oversupply. We have a couple of issues with this.

“First, for premium flower especially, you can’t assume fungibility like any other commodity. Second, perhaps anti-consensual, we don’t see a period of oversupply until mid-2021 at the earliest.”

How will winners be decided in the medical versus recreational sectors?

“The long-term winners in the medical space will be those that are investing in clinical trials, applying for patents and are backed by a strong medical team with experience,” according to the report.

Adult-use winners will have to create brands and value-add products, as well as deliver differentiated experiences.

Jefferies started coverage of nine Canadian marijuana firms:

  • Canopy Growth (NYSE: CGC, TSX: WEED) – Hold
  • Aurora Cannabis (NYSE: ACB, TSX: ACB) – Buy
  • Cronos Group  (Nasdaq: CRON, TSX: CRON) – Underperform
  • Hexo Corp. (NYSE: HEXO, TSX: HEXO) – Underperform
  • The Green Organic Dutchman (TSX: TGOD, OTC: TGODF) – Buy
  • CannTrust Holdings (TSX: TRST) – Buy
  • OrganiGram Holdings (TSX: OGI, OTC: OGRMF) – Buy
  • Emerald Health Therapeutics (TSX: EMH) – Hold
  • Flowr Corp. (TSX: FLWR) – Buy

To sign up for our weekly international cannabis business newsletter, click here.

3 comments on “Wall Street bank: Fears on cannabis commoditization overdone
  1. john ward on

    “If any cannabis (company) wants to claim large cap or even mega-cap future status, they need to have a strong position in the U.S.,” Jefferies analyst Owen Bennett wrote in the report”

    Thanks for the list, please provide more info on what these sharks own so that I can spend my money at local mom and pop cannabis companies. Prop 64 excluded the big players till 2023. This was done to allow the grey/black market operators time to come above board. The BCC changed that. Now we have big corporations and a massive black market underground comprised of former cannabis vendors that have been squeezed out of the game do to greed.
    But hey:
    For lack of a better word, greed is good. Greed is right, greed works. Greed clarifies, cuts through, and captures the essence of the evolutionary spirit. Greed, in all of its forms; greed for life, for money, has marked the upward surge of mankind.
    God bless America where greed is king!

    Reply
  2. Barry Cusitar on

    Sure there is some point to Greed, but the coming out of “Cannabis” and “Hemp” will be one of the best things to happen to the world in our lifetime. Why? Just the health ramifications alone – it is going to totally change medical treatment across the Globe, so many new health benefits and treatments being made and/or underway, the surface of which hasn’t even been scratched yet. So, to invest and make money while the world becomes a healthier, happier place at the same time is nothing but a big Win Win :)! God Bless Canada (and America too)!!!!

    Reply
  3. G. S. Myers on

    Those of us who have waited most of our lives for the legalization of cannabis should be happy with the progress. As long as the laws allow home grown and possession of herb we should not complain that the big, highly capitalized players will latch onto the opportunity. That’s the nature of free enterprise. Invest and profit. My biggest concern is that governments will tax it to a degree that they incent the black market to continue and thwart investors’ potential.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *